Biomed Industries Advances Next-Generation Oral Weight-Loss Pill into Phase 3 Trials
New Orleans, Wednesday, 10 June 2026.
Biomed Industries announced Phase 3 trials at ADA 2026 for a groundbreaking oral weight-loss pill that burns fat, preserves muscle mass, and offers long-term maintenance after stopping traditional injections.
Tackling the GLP-1 Dropout Crisis
The weight-loss drug sector has undeniably revolutionized modern medicine, but it harbors a significant vulnerability: patient retention [GPT]. While approximately 30 million individuals have utilized GLP-1 therapies, between 50% and 75% of patients abandon their treatment within a single year [1]. For patients using these medications solely for obesity without an underlying diabetes diagnosis, the attrition rate is even more pronounced. Data indicates that 64.8% of non-diabetic users discontinue within one year, escalating to 84.4% by the end of year two—representing a 19.6 percentage point jump in treatment abandonment over that 12-month period [1]. Recognizing this gap, Biomed Industries, Inc. seized the spotlight on June 10, 2026, at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, unveiling its strategy to address long-term weight management [1].
The BIOCOMBO-1 Blueprint: Monotherapy and Combination Strategies
To validate these ambitious claims, Biomed Industries presented its global Phase 3 clinical protocol on June 9, 2026, detailing a trial dubbed BIOCOMBO-1 [1]. This 68-week, randomized, double-blind, and placebo-controlled study will enroll approximately 466 overweight or obese adults who do not have diabetes [1]. The trial is uniquely structured to evaluate NA-931 at a 120 mg daily oral dose both as a standalone monotherapy and in a combination regimen with 12.5 mg of oral semaglutide [1].
A Crowded and Evolving Landscape at ADA 2026
Biomed’s strategic pivot toward muscle preservation and post-GLP-1 maintenance aligns perfectly with broader industry trends showcased at the ADA 2026 conference, which runs until June 18, 2026 [1]. Standard GLP-1 therapies have been linked to significant skeletal muscle loss, typically ranging from 25% to 40% of the total weight lost [3]. This side effect has spurred intense competition among pharmaceutical developers to engineer complementary treatments. For example, South Korea’s Hanmi Pharmaceutical utilized the ADA platform on June 7, 2026, to present data on a preclinical myostatin inhibitor aimed specifically at mitigating this muscle-wasting phenomenon [3].